Monte Nido & Affiliates Expands Eating Disorder Treatment with New Location in Manhattan
08 Nov 2023
Midtown program will expand access to care for adolescents and adults
NEW YORK, Nov. 8, 2023 /PRNewswire/ -- Monte Nido & Affiliates, one of the leading eating disorder treatment providers in the country, today announces the expansion and re-location of Monte Nido Manhattan Eating Disorder Day Treatment. The program, located in Midtown near Bryant Park, provides eating disorder treatment for adolescents and adults of all genders.
Continue Reading
Preview
Source: PRNewswire
Monte Nido Manhattan Eating Disorder Day Treatment
Preview
Source: PRNewswire
Monte Nido Manhattan Hosts Panel Discussion on Eating Disorders
"Eating disorders are on the rise and have the potential to affect individuals of all backgrounds and ages," said Cassie McLean, Chief Executive Officer of Monte Nido & Affiliates. "Expanding access to care for both adults and adolescents in one of the most populated areas in our country is more important than ever, because we believe recovery is possible for anyone with the right tools and support."
Through a Partial Hospitalization Program (PHP) and Intensive Outpatient Program (IOP), Monte Nido Manhattan provides personalized, evidence-based treatment for adults and adolescents, now in a more central location that is easily accessible from public transportation. Individuals will participate in personalized individual and group therapy, and benefit from clinical, medical, psychiatric and nutritional expertise while navigating real-life challenges.
"Monte Nido provides an individualized treatment approach to account for the unique needs of every individual," said Melissa Spann, PhD, LMHC, CEDS-C, Chief Clinical Officer of Monte Nido & Affiliates. "Our comprehensive system of care ensures we treat clients with a multidimensional approach and includes relational focus, trusted outcomes, cultural awareness and building resilience through a trauma-informed approach."
Given the significant prevalence of PTSD among individuals with eating disorders, Monte Nido Manhattan will provide evidence-based trauma treatments that incorporate cognitive processing therapy (CPT), a gold standard approach to trauma treatment. This innovative approach is backed by recent pioneering research that shows clients who experienced this integrated clinical approach improved significantly and remained improved six months following discharge.
Monte Nido Manhattan is the seventh Monte Nido & Affiliates program in the state of New York, complementing the day treatment program in Westchester, and residential programs in Glen Cove, River Towns, Rockland, Briarcliff Manor and Hudson Valley.
For more information, or to inquire about treatment at Monte Nido Manhattan, please visit www.montenido.com or call 888-228-1253.
About Monte Nido & Affiliates
Monte Nido & Affiliates is a leading provider of eating disorder treatment, offering inpatient, residential, and in-person and virtual day treatment programs. For over two decades, our expert staff of eating disorder professionals have delivered compassionate care, breakthrough outcomes, and long-term recovery for our clients. Founded in 1996, Monte Nido & Affiliates currently operates more than 50 programs across four distinct eating disorder program brands: Monte Nido, Walden, Rosewood and Clementine.
Contact: Abigail Cox
312-565-3900
[email protected]
SOURCE Monte Nido & Affiliates
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.